Recent news highlights AUNA's operational initiatives and financial progress across its key markets, including oncology expansion in Mexico, risk-sharing in Colombia, and revenue growth in Peru.

• AUNA's oncology initiatives continue to gain traction in Mexico, enhancing its specialized healthcare offerings and market presence [N1].
• The company employs a risk-sharing strategy in Colombia that supports revenue growth, indicating active management of market dynamics [N3].
• Post Q4 earnings, AUNA has been noted for solid financial performance and operational momentum [N6].
• Strong gains from Peru have been reported, suggesting positive developments in this key market [N8].
• AUNA delivered 7% revenue growth in Q4 2025, with the stock price responding positively [N6].
• The company is progressing toward its net leverage target, reflecting efforts to manage financial leverage [N7].
• AUNA has climbed 21.5% year-to-date, outperforming its industry peers, highlighting market recognition of its business progress [N2].

AUNA's expansion of oncology services in Mexico and implementation of risk-sharing strategies in Colombia indicate active efforts to enhance revenue streams and market penetration. The company's public-private partnership projects and facility leases demonstrate operational scale and infrastructure investment. Recent financial performance shows revenue growth and progress toward net leverage targets, suggesting disciplined financial management. These factors contribute to a narrative of operational strengthening and geographic diversification.

AUNA faces risks related to its controlling shareholder influence, which may lead to potential conflicts of interest and governance challenges. Liquidity ratios below 1.0 highlight working capital constraints that could impact operational flexibility. The company is exposed to legal and regulatory risks inherent in the healthcare industry, including medical malpractice and labor lawsuits. Political and economic instability in its operating countries, such as Peru, Colombia, and Mexico, may adversely affect business conditions and financial results.

AUNA's moat is supported by its established presence in multiple Latin American healthcare markets, including strategic public-private partnerships such as the Centro Ambulatorio Trecca PPP Agreement in Peru. Its diversified geographic footprint and specialized services like oncology provide competitive positioning. The company's controlling shareholder structure and governance framework may facilitate strategic decision-making and access to capital. However, the healthcare sector's regulatory environment and operational complexities in emerging markets present ongoing challenges.

• Controlling Shareholder Influence: Enfoca, the controlling shareholder, holds significant voting power and board representation, which could lead to conflicts of interest and decisions that may not align with all shareholders' interests.
• Liquidity Constraints: As of June 30, 2025, AUNA's current ratio was 0.91 and cash ratio 0.09, indicating potential short-term liquidity challenges that could affect operational and financial flexibility.
• Legal and Regulatory Risks: The company is involved in various legal proceedings typical of the healthcare sector, including medical malpractice and labor lawsuits, with provisions for probable losses recorded.
• Political and Economic Instability: Operating in Peru, Colombia, and Mexico exposes AUNA to risks from political, economic, and social instability, which could materially impact its business and financial performance.

• AUNA S.A. is a holding company conducting its business through subsidiaries primarily in healthcare services.
• The company operates in multiple countries including Peru, Colombia, and Mexico, with specific initiatives such as oncology services in Mexico and risk-sharing strategies in Colombia.
• AUNA's subsidiaries engage in public-private partnerships, such as the Centro Ambulatorio Trecca PPP Agreement in Peru, involving design, construction, financing, and operation of healthcare facilities.
• The company has a controlling shareholder, Enfoca, which owns approximately 72.9% of class B shares and has significant influence over governance and related party transactions.
• AUNA's board includes members affiliated with Enfoca, and related party transactions are subject to internal policies and board committee approvals.
• Financial snapshot as of 2025-06-30 shows cash and equivalents of PEN 174.7 million, current assets of PEN 1.715 billion, current liabilities of PEN 1.882 billion, resulting in a current ratio of 0.91 and a cash ratio of 0.09.
• For the six months ended 2025-06-30, AUNA reported revenue of PEN 1.094 billion and net income of PEN 84.0 million, with basic EPS of PEN 1.11 and diluted EPS of PEN 1.10.
• The company did not pay dividends in 2023, 2024, or 2025, and dividend payments depend on subsidiary earnings and distributions.
• AUNA is subject to various legal and administrative proceedings typical for its industry, with provisions for probable losses amounting to PEN 10.2 million as of December 31, 2025.
• Recent news highlights include oncology initiatives gaining traction in Mexico, risk-sharing strategies supporting revenue growth in Colombia, and strong gains from Peru.
• The company reported 7% revenue growth in Q4 2025 and has been noted for heading toward its net leverage target.
• AUNA's shares are listed on the NYSE since March 22, 2024, and on the Lima Stock Exchange since July 16, 2025.